Skip to content

A randomized controlled study of Zhu's Tiaojing Recipe on blood lipid in patients with obese polycystic ovary syndrome

A randomized controlled study of Zhu's Tiaojing Recipe on blood lipid in patients with obese polycystic ovary syndrome

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100005338
Enrollment
Unknown
Registered
2021-11-27
Start date
2021-11-24
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

Sponsors

Yueyang integrated traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.3 Inclusion Criteria (1) Women aged between 18 and 40; (2) Meet the diagnostic criteria of Western medicine for polycystic ovary syndrome; (3) BMI 25 kg/m2 or; (4) No hormone or lipid-lowering drugs were taken within 3 months before entering the study; (5) Patients signed informed consent and volunteered to take the test.

Exclusion criteria

Exclusion criteria: 1.4 Exclusion Criteria (1) persons younger than 18 or older than 40; (2) those who had used drugs and contraceptives affecting endocrine and lipid metabolism within 3 months before the study; (3) allergic to metformin; (4) Gynecological examination or B ultrasound examination of organic lesions of the uterus and accessories; (5) Diseases similar to the clinical and endocrine signs of PCOS due to other reasons, such as follicular membrane cell hyperplasia, ovarian or adrenal tumor, adrenal cortical hyperplasia, etc.; (6) patients with serious primary diseases such as heart disease, liver disease and kidney disease or mental illness; (7) Those who do not meet the inclusion criteria, do not use drugs as prescribed, cannot judge the efficacy or incomplete data affect the judgment of efficacy or safety.

Design outcomes

Primary

MeasureTime frame
Total effective rate of clinical efficacy;

Secondary

MeasureTime frame
Fasting plasma glucose;Follicle stimulating hormone;triglycerides;High-density lipoprotein;body mass index;TCM syndrome score;progesterone;Total cholesterol;weight;free fatty acids;testosterone;Estradiol;Prolactin;Waist hip ratio;Fasting insulin;Ovarian volume;Luteinizing hormone;Follicle diameter;Endometrial thickness;LH/FSH;Number of antral follicles;Low-density lipoprotein;

Countries

China

Contacts

Public ContactDong Li
yyyydongli@163.com18930565213

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026